Morgan Stanley reduced its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 23.3% during the first quarter, Holdings Channel reports. The fund owned 64,335 shares of the biopharmaceutical company’s stock after selling 19,537 shares during the period. Morgan Stanley’s holdings in Agios Pharmaceuticals were worth $3,756,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. C WorldWide Group Holding A S purchased a new position in Agios Pharmaceuticals during the first quarter worth $105,000. Bank of Montreal Can boosted its position in Agios Pharmaceuticals by 11.7% in the first quarter. Bank of Montreal Can now owns 2,068 shares of the biopharmaceutical company’s stock worth $121,000 after buying an additional 216 shares during the last quarter. Russell Investments Group Ltd. boosted its position in Agios Pharmaceuticals by 163.9% in the first quarter. Russell Investments Group Ltd. now owns 2,549 shares of the biopharmaceutical company’s stock worth $149,000 after buying an additional 1,583 shares during the last quarter. Advantage Investment Management LLC boosted its position in Agios Pharmaceuticals by 109.7% in the first quarter. Advantage Investment Management LLC now owns 3,250 shares of the biopharmaceutical company’s stock worth $190,000 after buying an additional 1,700 shares during the last quarter. Finally, Janney Montgomery Scott LLC purchased a new position in Agios Pharmaceuticals during the first quarter worth $257,000. 83.13% of the stock is owned by institutional investors.

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) traded down 0.57% during trading on Wednesday, hitting $57.84. 40,775 shares of the stock traded hands. The company’s market cap is $2.80 billion. The firm has a 50 day moving average price of $56.99 and a 200-day moving average price of $52.28. Agios Pharmaceuticals, Inc. has a one year low of $35.84 and a one year high of $67.74.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.57) by $0.21. Agios Pharmaceuticals had a negative return on equity of 68.15% and a negative net margin of 502.12%. The company had revenue of $11.30 million for the quarter, compared to the consensus estimate of $10.68 million. During the same quarter in the previous year, the firm posted ($1.47) EPS. The business’s revenue for the quarter was up 62.1% compared to the same quarter last year. Analysts anticipate that Agios Pharmaceuticals, Inc. will post ($6.90) earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Morgan Stanley Has $3.76 Million Position in Agios Pharmaceuticals, Inc. (AGIO)” was posted by Watch List News and is the property of of Watch List News. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright & trademark legislation. The correct version of this news story can be accessed at https://www.watchlistnews.com/morgan-stanley-has-3-76-million-position-in-agios-pharmaceuticals-inc-agio/1494697.html.

A number of equities analysts have weighed in on AGIO shares. BidaskClub raised shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 13th. Oppenheimer Holdings, Inc. set a $75.00 price objective on shares of Agios Pharmaceuticals and gave the company a “buy” rating in a research report on Sunday, June 11th. Cann reissued a “buy” rating and issued a $75.00 price objective on shares of Agios Pharmaceuticals in a research report on Sunday, June 11th. Canaccord Genuity set a $90.00 price target on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, May 18th. Finally, SunTrust Banks, Inc. reaffirmed a “buy” rating and set a $80.00 price target (up previously from $68.00) on shares of Agios Pharmaceuticals in a research report on Tuesday, August 8th. Five research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $74.75.

In other news, insider Scott Biller sold 2,146 shares of Agios Pharmaceuticals stock in a transaction dated Friday, July 7th. The shares were sold at an average price of $55.00, for a total transaction of $118,030.00. Following the sale, the insider now directly owns 8,410 shares in the company, valued at approximately $462,550. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Lewis Clayton Jr. Cantley sold 2,036 shares of Agios Pharmaceuticals stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $47.10, for a total transaction of $95,895.60. Following the sale, the director now owns 91,206 shares in the company, valued at $4,295,802.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 79,120 shares of company stock worth $4,557,207. 10.55% of the stock is owned by company insiders.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.

Want to see what other hedge funds are holding AGIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agios Pharmaceuticals, Inc. (NASDAQ:AGIO).

Institutional Ownership by Quarter for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.